NEWS & COMMENT

Europe

An Uncertain Start for a Brain Decade

BRUSSELS—U.S. neuroscientists may question whether President Bush's declaration of the 1990s as the Decade of the Brain has had a real impact on federal spending for neuroscience research, but the initiative can claim one definite achievement: It has sired a litter of copycat efforts in Europe. Italy, the Netherlands, Sweden, and Switzerland have all either already launched their own neurodecades, or are now doing so. And now those efforts have transcended the level of nationstates with the inauguration last week of the European Community's (EC) own "European Decade of Brain Research."

Like its U.S. counterpart, Europe's brain decade has questions of funding hanging over its head. In fact, many European scientists are braced for disappointment in the next few weeks, when the European Commission (the EC's executive) formally submits its request for the EC's next 5-year research budget, due to run from 1994. But that isn't the only thing that bothers European neuroscientists. Some are angry that the main professional organization for Europe's neuroscientists wasn't consulted by the task force of brain research experts that drew up the program. Worse, many neurobiologists are upset by what they see as a too-heavy emphasis on psychiatry and drug development and a failure to promote basic neuroscience.

Even at the launch ceremony in the Palais des Academies in Brussels, the program's future seemed clouded. Although the task force has proposed an annual budget of \$130 million, one commission science official confided that the figure is unrealistic. And while commission vice president Filippo Pandolfi enthusiastically endorsed the brain decade concept, Paolo Fasella, the commission's research director-general, was less effusive when quizzed about the details. Citing "subsidiarity"-the principle that restricts the EC to funding only those programs that can't be achieved at the national level-Fasella told Science that he'd have to look carefully at the proposal to see which parts should be supported by the EC and which should be left to its member states.

Most of the national efforts—which are being administered independently of the pan-European initiative—face similar uncertainty over funds. Italy, for instance, launched its brain decade in 1990. But Nobel laureate Rita Levi Montalcini of Rome's Institute of Neurobiology says that little has been done since then to make the program a reality. In Sweden, neuroscientists hope to bankroll their program through private donations. It's unrealistic to expect the Swedish Medical Research Council to spend more on neuroscience, explains neurobiologist Annica Dahlström of the University of Göteborg, since the agency already devotes 30% of its budget to the discipline.

But at least the national programs emphasize basic science, say the critics of the European decade. In their eyes the EC effort leans too far toward psychiatry and the drug industry and away from badly needed fundamental research into how the brain functions. Those concerns stem partly from the composition of the task force that has designed the program—it is dominated by neuropsychiatrists. And the outline proposal unveiled by the task force last week seems to confirm these fears, calling for more than two-thirds of the budget to be spent on projects linking academic researchers with drug company labs.

Task force head Julien Mendlewicz of the Free University of Brussels says a strong industry component is essential to make the proposal "politically attractive," given that the EC is mostly interested in supporting applied research. But many researchers say that a coordinated effort is needed most in basic neuroscience, where European efforts lack the critical mass to compete with the United States (*Science*, 24 April, p.468). "Both the psychiatrists and the pharmaceutical industry...pull in directions that aren't actually conducive to the development of neuroscience in Europe," says learning and memory researcher Steven Rose of Britain's Open University, voicing a concern held even by some members of the task force itself. "I think there's a lack of basic science [in the proposal for the European decade], compared to what's done in the United States," says one task force member, who asked not to be identified.

Further unsettling some basic researchers, the task force failed to consult formally with the European Neuroscience Association (ENA)—the only organization that can claim to speak for basic neurobiologists throughout Europe. But the French government has tried to heal the rift, in August appointing incoming ENA president Constantino Sotelo to the task force, which is still working on the fine print of the brain decade plan. Sotelo, a developmental neurobiologist from the Salpetrière Hospital in Paris, promises that "basic neuroscience will be well represented" in the final plan.

Europe's neurobiologists will want to hold him to his word. Even Mendlewicz, who supports the thrust toward psychiatry and drug development, warned at last week's launch ceremony that if the EC fails to back the initiative, all Europe can expect from the next 10 years is a brain drain of its best young neuroscientists to the United States. –Peter Aldhous

UK SCIENCE

Royal Society Suggests Remedies

Citation impact and morale are falling. The once plentiful Nobel Prizes are now few and far between. All the evidence points to a decline in British science. But what exactly is the problem? That's the question the elite Royal Society set out to answer in January 1991, when its president, Cambridge University mathematician Michael Atiyah, launched a wide-ranging inquiry into UK science policy. After consulting with more than 300 people, the society has now reached a diagnosis. And in a report on "The Future of the Science Base," released 1 October, it suggests some remedies.

For those scientists who wanted the Royal Society to add its influential voice to the many demanding a large increase in public research spending, the report will be a disappointment. While it does note that UK government science funding was squeezed over the past decade, it doesn't say just how much should be spent on science. "We have to take a more statestman-like view," Atiyah explains. Nor does the Royal Society call for sharp changes in existing funding mechanisms. Instead, the report blames the state of UK academic science largely on poor career structure, and that's where many of its suggestions are focused.

SCIENCE • VOL. 258 • 2 OCTOBER 1992

One major problem, the report notes, is that permanent faculty posts were cut back over the 1980s while the number of young scientists employed on short-term contracts continued to grow-making university research a blind alley career option for many young scientists and destroying morale. Indeed, there were 6000 more university research scientists and engineers on temporary contracts in 1990-91 than in 1977-78. "We have too many people who've been there too long on short-term contracts," says Atiyah. Among the society's solutions: Granting agencies should identify rising stars after a couple of postdocs and reward them with 5-year fellowships, rather than making them struggle along on 2-year grants until they land a faculty position. Also, the report says that employers should rapidly pick out the ones who aren't faculty material and give them training to ease the transfer out of academia—instead of simply discarding them after they reach their thirties.

Meanwhile, many of Britain's established scientists are kept away from the bench by heavy teaching and administrative duties. To solve that problem, and to help poorly paid Ph.D. students, the Royal Society borrows a